<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Topic</th>
<th>Abstract ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am - 9:00am</td>
<td>Registration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:50am- 10:00am</td>
<td>SESSION ONE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:50am</td>
<td>Welcome</td>
<td>Rajiv Khanna</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00am</td>
<td>Opening Plenary Lecture</td>
<td>Professor Dario Campana</td>
<td>Cellular immunotherapy of cancer</td>
<td>abs#001</td>
</tr>
<tr>
<td>9:30am</td>
<td>Keynote Lecture</td>
<td>Professor Michael Good</td>
<td>Modelling immunity to group A streptococcus (GAS) reveals that a failure of strain-specific immune induction may underlie the epidemic of streptococcal pyoderma: overcoming immune resistance through vaccination</td>
<td>abs#002</td>
</tr>
<tr>
<td>10:00am-10:30am</td>
<td>Morning Tea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30am-12:00pm</td>
<td>SESSION TWO: Advances in Immuno-oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30am</td>
<td>Chair: Associate Professor Phil Darcy</td>
<td>Professor Evan Newall</td>
<td>Identifying and profiling tumor specific T cells using mass cytometry and highly multiplexed peptide-MHC tetramer staining</td>
<td>abs#003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Marc Pellegrini</td>
<td>A vulnerable liaison - TNF, host cell IAPs and our pathogens</td>
<td>abs#004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Michele Teng</td>
<td>Superior power of neoadjuvant immunotherapy to eradicate metastatic disease</td>
<td>abs#005</td>
</tr>
<tr>
<td>11:30am</td>
<td>Discussion Forum – Advances in Immuno-oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Associate Professor Phil Darcy</td>
<td>Dr. Evan Newall, Dr. Marc Pellegrini and Dr. Michele Teng</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm - 1:00pm</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm - 2:00pm</td>
<td>SESSION THREE: CAR T cells – Preclinical Development to Clinical Application</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Professor Gabrielle Belz</td>
<td>Dr. Siok Tey</td>
<td>Safety Switches for T Cells</td>
<td>abs#007</td>
</tr>
</tbody>
</table>
A/Prof. Phil Darcy
Enhancing adoptive cellular therapy by targeting tumor-induced immunosuppression

Mariusz Skwarczynski
Liposomes in intranasal and oral delivery of lipopeptide-based vaccines

SESSION FOUR: Clinical Trial Designs for Immunotherapy and Novel Vaccines
Chair: Dr Ian Barr

Professor Ranjeny Thomas
Antigen-specific tolerizing immunotherapy for rheumatoid arthritis: towards precision medicine

Dr. Suzanne Elliott
Critical Design Elements for a Successful Vaccine Trial

Mehfuz Zaman
Development of a liposomal mucosal vaccine delivery system against an upper respiratory tract pathogen (Group A Streptococcus)

SESSION FIVE: Young Investigators Abstract Presentations
Chair: Dr Michelle Wykes

Ms. Nicola MacLennan
Lipovaxin, a versatile liposomal vaccine delivery platform, combining antigens with immune-stimulatory particles for improved immune responses

Dr Stacy Scott
New Zealand regulation of medicines that contain genetically modified organisms

Ms. Louise A Carolan
Characterisation of the localised immune response in the respiratory tract of ferrets following infection with influenza A and B viruses

SESSION SIX: Innate Immune Response and Vaccine Design
Chair: Dr Christian Engwerda

Dr. Florent Ginhoux
Dendritic Cell and Macrophage Ontogeny

**Associate Professor Michele Grimbaldeston**
Novel approaches to control mast cell function in allergic inflammation

**Mr Branka Grubor-Bauk**
New life from dead cells: A novel necrotic cell vaccine, encoding the hepatitis C virus NS3 protein, induces superior cell mediated immune responses, compared to those of a live cell vaccine.

**Ms. Victoria Ozberk**
Development of a novel intranasal vaccine to prevent upper respiratory tract infection by group A streptococcus

**Noushin Jaberolansar**
Design and efficacy evaluation of peptide-based vaccine against RSV

---

5:35pm - 7:00pm  **Welcome Reception**

---

**THURSDAY 21st APRIL, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:50am - 10:00am   | **SESSION SEVEN: Adoptive Immunotherapy**  
|                    | Chair: Professor Dario Campana                                      |
| 8:50am             | Plenary Lecture II  
|                    | Professor Geoff Hill  
|                    | Novel cytokine and cellular therapy in transplantation               |
| 9:20am             | **Discussion Forum: Adoptive Immunotherapy**  
|                    | Chair: Professor Rajiv Khanna                                       |
|                    | Professor Geoff Hill, Associate Professor Phil Darcy and Professor  |
|                    | Dario Campana                                                      |
| 10:00am-10:30am    | Morning Tea                                                        |
| 10:30am-12:00pm    | **SESSION EIGHT: Effector Memory Immune Cells and Vaccination**    |
|                    | Chair: Associate Professor Kristen Radford                          |
|                    | Professor Steve Turner  
|                    | Genome wide mapping of histone modifications identifies novel regulatory elements that underpin virus-specific CD8+ T cell differentiation |
Dr. Tonia Woodberry
Dendritic cells and Plasmodium: early infection compromises CD1c myeloid but not plasmacytoid dendritic cells

Ms. Susanna Ng
Characterising the role of group 1 innate lymphoid cells during malaria

Dr. Kristen Radford
Targeting human Clec9A+ dendritic cells for immunotherapy

Dr. Michelle Wykes
PD-L2 is crucial for establishing effective CD4+ Th1 immunity against malaria

Ms. Marcela Montes do Oca
Type I interferons are potent immune regulators in humans with blood-stage Plasmodium falciparum infection

Mr. Branka Grubor-Bauk
Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell mediated immunity in mice and pigs

Mr. Nicholas Ede
Development of a clinical–ready polyclonal anti-HER-2/neu vaccine against breast and gastric cancer

Professor Eric Gowans
A novel replicating recombinant human rhinovirus vaccine that generates mucosal and systemic immunity to HIV-1 Gag & Tat

Professor Andreas Suhrbier
Horse immunoglobulin for treatment of Ebola virus infections
Ms. Heidi A Peck
evaluation of influenza B viruses for use in cell-based quadrivalent influenza vaccines

Ms. Champa Ratnatunga
Multi-parametric immunoprofiling in Mycobacterium abscessus infection reveals distinct T cell exhaustion and dysfunction patterns in at-risk patient groups

SESSION ELEVEN: Commercialisation of Vaccine and Immunotherapeutic Drugs
Chair: Professor Andreas Suhrbier
Dr. Goslik Schepers
Commercialising I-O technologies

Dr. Neil Finlayson
Commercialisation of Vaccine and Immunotherapeutic Drugs

Poster and Networking Function

Conference Dinner

FRIDAY 22nd APRIL, 2016

SESSION TWELVE – Cellular Immune Regulation and Immunotherapy
Chair: Professor Ranjeny Thomas
Plenary Lecture III
Professor Barbara Fazekas de St Groth
Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease

Keynote Lecture IV
Professor Jamie Rossjohn
Immune sensing of vitamin B metabolites

SESSION THIRTEEN: Immunotherapeutics for Chronic Diseases
Chair: Professor Steve Turner
Dr. Laura Mackay
Development and Function of Tissue-Resident Lymphocytes
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50am-11:40am</td>
<td>Morning Tea</td>
</tr>
</tbody>
</table>
| 11:40am-12:30pm | SESSION FOURTEEN: Immunotherapy and Vaccine Development – Bench to Bedside  
Chair: Professor Andreas Suhrbier |
|              | Professor Eric Reynolds                                                
A therapeutic vaccine for *Porphyromonas gingivalis*-mediated chronic disease  
abs#043                                      |
|              | Dr Frédéric Triebel                                                   
LAG 3: Validation of Next Generation Checkpoint Pathways                    
abs#044                                    |
|              | Dr. Bill Dougall                                                      
Challenges and Considerations in Oncology Drug Development: Lessons from Denosumab  
abs#045                                      |
| 12:40pm-12:45pm | Closing Announcements and Best Poster and Oral Presentations         |